| Stage | ASTE | % of rev | CAT | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $408M | 100.00% | $20.7B | 100.00% | CAT ×50.68 |
| Gross profit | $107M | 26.17% | $7.3B | 35.54% | CAT +9.4pp |
| Operating income | $20M | 5.00% | $4.2B | 20.38% | CAT +15.4pp |
| Pre-tax income | $15M | 3.68% | $4.2B | 20.40% | CAT +16.7pp |
| Net income | $11M | 2.57% | $3.3B | 15.89% | CAT +13.3pp |
| Stage | ASTE | CAT | Gap · A − B |
|---|---|---|---|
| Revenue | $408M100.00% | $20.7B100.00% | CAT ×50.68 |
| Gross profit | 26.17%$107M | 35.54%$7.3B | CAT +9.4pp |
| Operating income | 5.00%$20M | 20.38%$4.2B | CAT +15.4pp |
| Pre-tax income | 3.68%$15M | 20.40%$4.2B | CAT +16.7pp |
| Net income |
| 2.57%$11M |
| 15.89%$3.3B |
| CAT +13.3pp |
None
No disclosed counterparties: ASTE.